GANIRELIX ACETATE for PCOS
Ganirelix acetate is listed as an early-phase clinical candidate for PCOS acting as a gonadotropin-releasing hormone receptor antagonist per Open Targets.
Hypothesized mechanism
By antagonizing the GnRH receptor, ganirelix acetate suppresses pituitary gonadotropin (LH/FSH) release, potentially correcting the LH-driven hormonal dysregulation characteristic of PCOS.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 5 of 10 overall, a emerging reading, from a pathway rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Only a single source (Open Targets) is cited, providing one line of evidence (a drug-target-indication association). No independent mechanistic lines converge here; it is a single database annotation.
Rigor
The claim reflects a clinical candidate at EARLY_PHASE_1 stage for PCOS, which is human-relevant in intent, but no actual study data, models, or outcomes are provided—only a database annotation of clinical stage.
Specificity
The mechanism is highly specific: ganirelix acetate acts as a gonadotropin-releasing hormone receptor antagonist on the GnRH receptor, a precisely named molecular target per the Open Targets claim.
Plausibility
GnRH receptor antagonism is mechanistically relevant to PCOS given the role of LH/FSH dysregulation, and the EARLY_PHASE_1 listing supports a plausible target-phenotype fit, but no phenotypic or outcome data are shown to confirm benefit.
Consistency
There is only one claim, so no conflicting signals exist, but a single annotation cannot demonstrate convergence of multiple mechanistic signals pointing the same way.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), GANIRELIX ACETATE (a Protein) is a clinical candidate for PCOS (maximum clinical stage EARLY_PHASE_1); its mechanism of action is Gonadotropin-releasing hormone receptor antagonist on target gonadotropin releasing hormone receptor. Open Targets · mechanistic ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →